Long-term effects of growth hormone therapy on patients with prader-willi syndrome

Acta Paediatrica, International Journal of Paediatrics

Volumn 99, Issue 11, 2010, Pages 1712-1718

  Sipilä, Ilkka ^a   Sintonen, Harri ^a   Hietanen, Heikki ^b   Apajasalo, Marjo ^a   Alanne, Soili ^c   Viita, Anna Mari ^d   Leinonen, Eeva ^d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Deaconess Hospital Diacor   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^d Oy Eli Lilly Finland Ab   (Finland)

Author keywords

Adult height; Growth; Prader willi syndrome; Recombinant human growth hormone

Indexed keywords

GLUCOSE; HUMAN GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; BODY COMPOSITION; BODY HEIGHT; BODY WEIGHT; CATCH UP GROWTH; CHILD; CHOLESTEATOMA; CLINICAL ARTICLE; DEPRESSION; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASE; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; LONG TERM CARE; MALE; OBESITY; PRADER WILLI SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM PROLAPSE; SCHOOL CHILD; SLEEP APNEA SYNDROME; SLEEP PATTERN; TREATMENT DURATION;

ADOLESCENT; BODY COMPOSITION; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; MALE; OBESITY; PRADER-WILLI SYNDROME; QUALITY OF LIFE; RECOMBINANT PROTEINS; SLEEP DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649732369     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2010.01904.x     Document Type: Article

References (30)

1. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M, on behalf of speakers and contributors at the Second Expert Meeting of the Comprehensive Care of Patients with PWS. Recommendations for the diagnosis and management of Prader-Willi Syndrome. J Clin Endocrinol Metab 2008;93:4183-97.
2. Cassidy SB. Prader-Willi syndrome. J Med Genet 1997; 34: 917-23.
3. Karlberg J, Engström I, Karlberg P, Fryer JG. Analysis of linear growth using a mathematical model. I. From birth to three years. Acta Paediatr Scand 1987; 76: 478-88. (Pubitemid 17074819)
4. Comprehensive care of patients with PWS - consensus, questions and future directions. Second Expert Meeting. 26-27 October 2006, Toulouse. Report. http://www.chutoulouse.fr/ IMG/pdf/2emecongresinternExpertsPWS.pdf
5. Butler MG, Meaney FJ. Standards for selected anthropometric measurements in Prader-Willi syndrome. Pediatrics 1991; 88: 853-60.
6. Corrias A, Bellone J, Beccaria L, Bosio L, Trifiró G, Livieri C, et al. GH/ IGF-I axis in Prader-Willi syndrome: Evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest 2000; 23: 84-9.
7. Burman P, Ritzén EM, Lindgren AC. Endocrine dysfunction in Prader-Willi syndrome: A review with special reference to GH. Endocr Rev 2001; 22: 787-99.
8. Lindgren AC, Hagenä s L, Müller J, Blichfeldt S, RosenborgM, Brismar T, et al. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr 1998; 87: 28-31.
9. Thacker MJ, Hainline B, St. Dennis-Feezle L, Johnson NB, Pescovitz OH. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm Res 1998; 49: 216-20.
10. Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study. J Pediatr 1999; 134: 215-21.
11. Tauber M. Effects of growth hormone treatment in children presenting with Prader-Willi syndrome: The KIGS experience. In: Ranke MB, Price DA, Reiter EO, editors. Growth hormone therapy in Pediatrics-20 years of KIGS. Basel: Karger, 2007: 377-87.
12. Festen DAM, Hokken-Koelega ACS. Breathing disorders in Prader-Willi syndrome: The role of obesity, growth hormone treatment and upper respiratory tract infections. Expert Rev Endocrinol Metab 2007; 2: 529-37.
13. Camfferman D, McEvoy RD, O'Donoghue F, Lushington K. Prader Willi Syndrome and excessive daytime sleepiness. Sleep Med Rev 2008; 12: 65-75.
14. Wilson SS, Cotterill AM, Harris MA. Growth hormone and respiratory compromise in Prader-Willi Syndrome. Arch Dis Child 2006; 91: 349-50.
15. Fillion M, Deal C, Van Vliet G. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome. J Pediatr 2009; 154: 230-3.
16. Lindgren AC, Hellström LG, Ritzén EM, Milerad J. Growth hormone treatment increases CO2 response, ventilation and central inspiratory drive in children with Prader-Willi syndrome. Eur J Pediatr 1999; 158: 936-40.
17. Miller J, Silverstein J, Shuster J, Driscoll DJ, Wagner M. Shortterm effects of growth hormone on sleep abnormalities in Prader- Willi syndrome. J Clin Endocrinol Metab 2006; 91: 413-7.
18. Lee PDK. Growth hormone and mortality in Prader-Willi syndrome. GGH 2006; 22: 17-23.
19. Ranke M, Haber P. Growth hormone stimulation tests. In: Ranke MB, editor. Functional Endocrinologic Diagnostics in Children and Adolescents. Mannheim: J&J Verlag, 1992: 61-75.
20. Boettcher C, Schaefer M, Wudy SA, Blum WF. Cross-calibration of IGF-I and IGFBP-3 assays to obtain comparable values. Abstract. 45th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) 2006, Rotterdam, The Netherlands.
21. Blum WF, Schweizer R. Insulin-like growth factors and their binding proteins. In Ranke MB, editor. Diagnostics of endocrine function in children and adolescents. Basel: Karger, 2003, 166-99.
22. Pere A. Comparison of two methods for transforming height and weight to normality. Ann Hum Biol 2000; 27: 35-45.
23. Sorva R, Tolppanen EM, Perheentupa J. Variation of growth in length and weight of children. I. Years 1 and 2. Acta Paediatr Scand 1990; 79: 490-7. (Pubitemid 20185308)
24. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist, 2nd edn. Stanford, CA: Stanford University Press, 1959: 256.
25. Apajasalo M, Sintonen H, Holmberg C, Sinkkonen J, Aalberg V, Pihko H, et al. Quality of life in early adolescence: A sixteendimensional health-related measure (16D). Qual Life Res 1996; 5: 205-11. (Pubitemid 26180668)
26. Sintonen H. The 15D instrument of health-related quality of life: Properties and applications. Ann Med 2001; 33: 328-36. (Pubitemid 32675373)
27. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6.
28. Caliandro P, Grugni G, Padua L, Kodra Y, Tonali P, Gargantini L, et al. Quality of life assessment in a sample of patients affected by Prader-Willi syndrome. J Paediatr Child Health 2007; 43: 826-30.
29. Festen DAM, de Lind Van Wingaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, et al. Randomized controlled GH trial: Effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2008; 69: 443-51.
30. Whitman BY, Myears S, Carrel A, Allen D. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: A 2-year, controlled study. Pediatrics 2002; 109: E35.